This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Insider Trading Alert - MNTA, CSCO And ANSS Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, May 21, 2014, 140 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $401.00 to $744,000,000.00.

Highlighted Stocks Traded by Insiders:

Momenta Pharmaceuticals (MNTA) - FREE Research Report

Wheeler Craig A, who is President at Momenta Pharmaceuticals, sold 1,688 shares at $12.08 on May 21, 2014. Following this transaction, the President owned 376,164 shares meaning that the stake was reduced by 0.45% with the 1,688-share transaction.

Kaundinya Ganesh Venkataraman, who is Senior V.P., Research at Momenta Pharmaceuticals, sold 227 shares at $12.08 on May 21, 2014. Following this transaction, the Senior V.P., Research owned 394,648 shares meaning that the stake was reduced by 0.06% with the 227-share transaction.

Shea Richard P, who is Svp, Cfo at Momenta Pharmaceuticals, sold 227 shares at $12.08 on May 21, 2014. Following this transaction, the Svp, Cfo owned 179,074 shares meaning that the stake was reduced by 0.13% with the 227-share transaction.

Bishop John E, who is Senior VP, Pharmaceutical Scie at Momenta Pharmaceuticals, sold 227 shares at $12.08 on May 21, 2014. Following this transaction, the Senior VP, Pharmaceutical Scie owned 110,625 shares meaning that the stake was reduced by 0.2% with the 227-share transaction.

Leicher Bruce, who is SVP & General Counsel at Momenta Pharmaceuticals, sold 227 shares at $12.08 on May 21, 2014. Following this transaction, the SVP & General Counsel owned 127,774 shares meaning that the stake was reduced by 0.18% with the 227-share transaction.

Roach James M., who is Senior VP, Development and Chi at Momenta Pharmaceuticals, sold 250 shares at $12.08 on May 21, 2014. Following this transaction, the Senior VP, Development and Chi owned 104,070 shares meaning that the stake was reduced by 0.24% with the 250-share transaction.

The shares most recently traded at $11.98, down $0.10, or 0.83% since the insider transaction. Historical insider transactions for Momenta Pharmaceuticals go as follows:

  • 4-Week # shares sold: 2,753
  • 12-Week # shares sold: 3,513
  • 24-Week # shares sold: 77,436

The average volume for Momenta Pharmaceuticals has been 1.0 million shares per day over the past 30 days. Momenta Pharmaceuticals has a market cap of $620.8 million and is part of the health care sector and drugs industry. Shares are down 34.05% year-to-date as of the close of trading on Wednesday.

Momenta Pharmaceuticals, Inc., a biotechnology company, is engaged in the structural characterization, process engineering, and biologic systems analysis of complex molecules in the areas of complex generics, biosimilars, and novel drugs. Currently, there are 3 analysts who rate Momenta Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on MNTA - FREE

TheStreet Quant Ratings rates Momenta Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Momenta Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs